PODD Q2 Deep Dive: Retention Challenges in Type 2 Diabetes Temper Growth Outlook

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 23.5% year on year to $801.7 million. On the other hand, next quarter’s revenue guidance of $833.4 million was less impressive, coming in 1.6% below analysts’ estimates. Its non-GAAP profit of $1.66 per share was 14.3% above analysts’ consensus estimates.

Is now the time to buy PODD? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the company’s type 2 diabetes segment. While broad-based demand for Omnipod drove growth across both U.S. and international markets, CEO Ashley McEvoy acknowledged that lower-than-expected retention rates among new type 2 users weighed on results. McEvoy stated, “We should have identified the issue sooner,” signaling a more cautious approach to commercial execution and customer onboarding for this group.

Looking ahead, Insulet’s updated guidance reflects a more measured view of U.S. growth, tempered by ongoing efforts to improve retention and utilization among type 2 customers. Management is prioritizing support initiatives such as an expanded customer care team, revised sales compensation to reward retention, and a new technology platform to enhance onboarding. CFO Flavia Pease cautioned that revised forecasts “do not assume improvements from the actions we are taking to improve retention and utilization,” emphasizing the company will monitor results over coming months before updating its long-term outlook.

Key Insights from Management’s Remarks

Management attributed the quarter’s growth to continued Omnipod adoption but highlighted early retention issues with type 2 users as the primary headwind shaping performance and outlook.

• Type 2 retention shortfall: Insulet experienced lower-than-expected retention rates among new type 2 diabetes users, particularly in the first 90 days after starting therapy. Management noted that this trend, more pronounced than anticipated, prompted a reevaluation of commercial and support models for this segment.
• Omnipod Discover platform launch: The company rolled out Omnipod Discover, a cloud-based tool designed to help patients and providers monitor trends, personalize therapy, and improve outcomes. Early feedback suggests the platform may enhance engagement and increase retention rates, especially among newer users unfamiliar with automated insulin delivery (AID) systems.
• Sales force and support model overhaul: Insulet is expanding its customer care team and changing sales force incentives to prioritize long-term retention rather than just new customer starts. Management believes these changes will address onboarding pain points and better support type 2 users through their initial therapy period.
• International expansion momentum: Omnipod 5 became the leading insulin pump for new users in Australia, and the company recently launched in Spain. These moves are broadening Insulet’s reach and diversifying growth drivers beyond the U.S. market.
• Stable pricing and access advances: Despite competitive pressures, management reported stable pricing in the U.S. and highlighted success in expanding insurance coverage and reducing prior authorization hurdles, supporting continued new customer adoption.

Drivers of Future Performance

Insulet’s outlook is shaped by its efforts to address onboarding challenges in type 2 diabetes, ongoing international growth, and the pipeline of new product launches.

• Retention improvement initiatives: Management is investing in a higher-touch onboarding model for type 2 users, including personalized support and technology enhancements. While early pilot programs have shown promise, CFO Flavia Pease emphasized that current guidance does not factor in potential improvements until sustained evidence emerges.
• Impact of new product pipeline: Insulet is advancing algorithm updates to its Omnipod systems, with Omnipod 6 scheduled for launch in 2027 and a fully closed-loop system for type 2 diabetes in development. Management expects these innovations to drive category adoption and address unique challenges in the type 2 segment.
• International and payer channel growth: Continued expansion in international markets and increased coverage by payers are expected to offset U.S. headwinds. Management raised its international growth outlook based on strong first-half performance and ongoing insurance wins, positioning these markets as a critical growth lever.

Catalysts in Upcoming Quarters

Looking ahead, our team will watch (1) whether Insulet’s onboarding and support initiatives for type 2 customers translate into improved retention, (2) the pace of international expansion and Omnipod adoption in new markets like Spain, and (3) progress on the pipeline, particularly the development timelines for Omnipod 6 and the fully closed-loop system for type 2 diabetes. Execution on these priorities will be key to restoring investor confidence.

Insulet currently trades at $132.28, down from $166.82 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.